Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3CNS 3Thoracic 2Sarcoma 2Head & Neck 2Endocrine 2Breast 2Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Thyroid Neoplasms 8Thyroid Cancer, Papillary 5Carcinoma, Medullary 5Carcinoma, Non-Small-Cell Lung 4Thyroid Diseases 3Colonic Neoplasms 3Breast Neoplasms 3Thoracic Neoplasms 2Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms by Site 2Neoplasms 2Lung Neoplasms 2Lung Diseases 2Head and Neck Neoplasms 2Endocrine System Diseases 2Endocrine Gland Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Thyroid Carcinoma, Anaplastic 1Sarcoma 1Pancreatic Neoplasms 1Myofibromatosis 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adenocarcinoma, Follicular 1

Interventions

Peripheral Blood Stem Cell Transplantation 3Filgrastim 3Cisplatin 3selpercatinib 2pembrolizumab 2Etoposide 2Carboplatin 2regorafenib 1pentetreotide 1pazopanib 1etoposide phosphate 1epothilone B 1entrectinib 1durvalumab 1carbon-11 methionine 1cabozantinib 1aflibercept 1Thiotepa 1Temozolomide 1Tamoxifen 1Surveys and Questionnaires 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Nivolumab 1NEO212 1Molecular Diagnostic Techniques 1Methionine 1MLN 8237 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × selpercatinib × Head & Neck × Clear all
NCT03157128 2026-04-16

LIBRETTO-001

Eli Lilly and Company

Phase 1/2 Active not recruiting
857 enrolled 24 charts 3 FDA
BreastCNSEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Medullary

NCT03899792 2026-01-06

LIBRETTO-121

Eli Lilly and Company

Phase 1/2 Active not recruiting
36 enrolled 13 charts 2 FDA
BreastCNSEndocrineGastrointestinalHead & NeckSarcomaThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡